Drug Profile
KiroTAC
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Kiromic
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute myeloid leukaemia; Breast cancer; Non-small cell lung cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA